BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 22244781)

  • 1. A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer.
    Devroey P; Pellicer A; Nyboe Andersen A; Arce JC;
    Fertil Steril; 2012 Mar; 97(3):561-71. PubMed ID: 22244781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients.
    Arce JC; La Marca A; Mirner Klein B; Nyboe Andersen A; Fleming R
    Fertil Steril; 2013 May; 99(6):1644-53. PubMed ID: 23394782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, assessor-blinded trial comparing highly purified human menotropin and recombinant follicle-stimulating hormone in high responders undergoing intracytoplasmic sperm injection.
    Witz CA; Daftary GS; Doody KJ; Park JK; Seifu Y; Yankov VI; Heiser PW;
    Fertil Steril; 2020 Aug; 114(2):321-330. PubMed ID: 32416978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cumulative live birth rates after one ART cycle including all subsequent frozen-thaw cycles in 1050 women: secondary outcome of an RCT comparing GnRH-antagonist and GnRH-agonist protocols.
    Toftager M; Bogstad J; Løssl K; Prætorius L; Zedeler A; Bryndorf T; Nilas L; Pinborg A
    Hum Reprod; 2017 Mar; 32(3):556-567. PubMed ID: 28130435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.
    Propst AM; Bates GW; Robinson RD; Arthur NJ; Martin JE; Neal GS
    Fertil Steril; 2006 Jul; 86(1):58-63. PubMed ID: 16753156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of highly purified human menopausal gonadotropin vs. recombinant follicle-stimulating hormone in first-cycle in vitro fertilization-intracytoplasmic sperm injection patients.
    Hompes PG; Broekmans FJ; Hoozemans DA; Schats R;
    Fertil Steril; 2008 Jun; 89(6):1685-93. PubMed ID: 17681325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of in vitro fertilization following stimulation with highly purified hMG or recombinant FSH in downregulated women of advanced reproductive age: a prospective, randomized and controlled trial.
    Ye H; Huang G; Pei L; Zeng P; Luo X
    Gynecol Endocrinol; 2012 Jul; 28(7):540-4. PubMed ID: 22390186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High ovarian response does not jeopardize ongoing pregnancy rates and increases cumulative pregnancy rates in a GnRH-antagonist protocol.
    Fatemi HM; Doody K; Griesinger G; Witjes H; Mannaerts B
    Hum Reprod; 2013 Feb; 28(2):442-52. PubMed ID: 23136144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles.
    Barrenetxea G; Agirregoikoa JA; Jiménez MR; de Larruzea AL; Ganzabal T; Carbonero K
    Fertil Steril; 2008 Mar; 89(3):546-53. PubMed ID: 17531989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial.
    Andersen AN; Devroey P; Arce JC
    Hum Reprod; 2006 Dec; 21(12):3217-27. PubMed ID: 16873892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of live birth rates and cumulative ongoing pregnancy rates between Europe and North America after ovarian stimulation with corifollitropin alfa or recombinant follicle-stimulating hormone.
    Boostanfar R; Mannaerts B; Pang S; Fernandez-Sanchez M; Witjes H; Devroey P;
    Fertil Steril; 2012 Jun; 97(6):1351-8. PubMed ID: 22459628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles.
    Lin MH; Wu FS; Lee RK; Li SH; Lin SY; Hwu YM
    Fertil Steril; 2013 Nov; 100(5):1296-302. PubMed ID: 23993928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of frozen-thawed embryo transfer in women aged 35 to 42 years from the PURSUE randomized clinical trial.
    Boostanfar R; Gates D; Guan Y; Gordon K; McCrary Sisk C; Stegmann BJ
    Fertil Steril; 2016 Aug; 106(2):300-305.e5. PubMed ID: 27090863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The J-Tip Needle-Free Injection System in controlled ovarian hyperstimulation in in vitro fertilization: a pilot study.
    Lavery SA; El-Shawarby SA; Turner C; Trew G
    Fertil Steril; 2008 Nov; 90(5):1969-72. PubMed ID: 18166182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women pretreated with oral contraceptives before in vitro fertilization.
    Barmat LI; Chantilis SJ; Hurst BS; Dickey RP
    Fertil Steril; 2005 Feb; 83(2):321-30. PubMed ID: 15705369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly purified hMG versus recombinant FSH in ovarian hyperstimulation with GnRH antagonists--a randomized study.
    Bosch E; Vidal C; Labarta E; Simon C; Remohi J; Pellicer A
    Hum Reprod; 2008 Oct; 23(10):2346-51. PubMed ID: 18583332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy of highly purified urinary FSH versus recombinant FSH in volunteers undergoing controlled ovarian stimulation for in vitro fertilization: a randomized, multicenter, investigator-blind trial.
    Baker VL; Fujimoto VY; Kettel LM; Adamson GD; Hoehler F; Jones CE; Soules MR
    Fertil Steril; 2009 Apr; 91(4):1005-11. PubMed ID: 18367182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multifollicular recruitment in combination with gonadotropin-releasing hormone antagonist increased pregnancy rates in intrauterine insemination cycles.
    Gómez-Palomares JL; Acevedo-Martín B; Chávez M; Manzanares M; Ricciarelli E; Hernández ER
    Fertil Steril; 2008 Mar; 89(3):620-4. PubMed ID: 17678911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study.
    Vuong TN; Ho MT; Ha TD; Phung HT; Huynh GB; Humaidan P
    Fertil Steril; 2016 Feb; 105(2):356-63. PubMed ID: 26523330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Corifollitropin alfa followed by rFSH in a GnRH antagonist protocol for poor ovarian responder patients: an observational pilot study.
    Polyzos NP; Devos M; Humaidan P; Stoop D; Ortega-Hrepich C; Devroey P; Tournaye H
    Fertil Steril; 2013 Feb; 99(2):422-6. PubMed ID: 23084565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.